Targets

BTK

6 articles

PharmacologyDrug Metabolism and Disposition (ASPET)

Human ADME of remibrutinib: rapid uptake, heavy metabolism, mainly fecal elimination

  • A radiolabelled oral dose plus intravenous microdoses in healthy volunteers mapped how the covalent BTK inhibitor remibrutinib is absorbed, distributed and cleared at steady state.
  • The drug was taken up quickly, spread widely into tissues and was extensively metabolised, with most elimination through the feces.
  • Radioactivity recovery was incomplete after oral dosing but nearly complete after the intravenous microdose, which helps separate absorption from clearance.
  • No circulating metabolite made up a major share of drug-related material, and the drug was well tolerated.
PointsBased on the abstract

Incomplete recovery after the oral dose but near-complete after the IV microdose suggests the loss sits in the absorption phase rather than in a tissue sink, and the microdose is what lets you separate that from clearance. For a covalent inhibitor, also ask how much label stays irreversibly on protein. Extensive metabolism with fecal dominance makes a hepatic-enzyme DDI study the sensible next step.

Industry NewsNovartisSTAT News

Novartis's remibrutinib cuts relapses versus teriflunomide in two pivotal MS trials

  • The REMODEL-1 and REMODEL-2 Phase 3 trials compared oral BTK inhibitor remibrutinib with teriflunomide in relapsing multiple sclerosis.
  • Both met the primary endpoint of lower annualized relapse rate, and MRI lesion measures also favored remibrutinib.
  • Novartis reported no liver safety signal and a positive trend on disability progression, and plans regulatory submissions.
PointsBased on public reports

The BTK class has been hurt in MS by liver-safety worries, so a clean liver profile is as important as the relapse benefit. Teriflunomide is an easy comparator, though, and the real contest is against high-efficacy anti-CD20 antibodies and other BTK inhibitors such as Sanofi's tolebrutinib; disability data will decide where remibrutinib fits.

PharmacologyBritish Journal of Pharmacology (Wiley)

Review: measuring covalent inhibitor kinetics and linking them to in vivo effect

  • Lead selection leans on equilibrium IC50 values, which ignore how drug and target levels shift over time; this matters most for irreversible covalent drugs.
  • The review surveys assays for kinact and KI: progress curves, multi-timepoint IC50 fitting for library triage, mass spectrometry for adducts and sites, SPR/NMR, and washout experiments for reversibility and residence time.
  • It then links these rates to pharmacology via protein turnover, target vulnerability and pharmacokinetics, using BTK, JAK3, KRAS G12C and EGFR cases.
PointsBased on the abstract

On a covalent hit, an IC50 from a single timepoint says little, because potency drifts with incubation time and ranking by it can bury the compound with the best kinact/KI. Translation is the harder part: in vivo occupancy depends on how fast the target is resynthesized, so a fast-turnover protein can blunt even a well-optimized warhead. Measure turnover before trusting the kinetics.

Medicinal ChemistryEuropean Journal of Medicinal Chemistry

Review maps covalent kinase inhibitors across EGFR, BTK, FGFR and JAK3

  • This is a review article, not a primary study, covering 35 approved and investigational covalent kinase inhibitors.
  • It focuses on four families that target a non-catalytic cysteine near the ATP pocket: EGFR (Cys797), BTK (Cys481), FGFR (Cys488) and JAK3 (Cys909).
  • Each inhibitor is discussed for discovery history, binding mode, SAR, indications and synthesis, along with off-target toxicity and acquired resistance such as EGFR C797S.
PointsBased on the abstract

Four cysteines, four very different risk profiles. Cys481 in BTK and Cys797 in EGFR are well-validated handles, but the C797S escape mutation shows the weakness: lose the nucleophile and the whole warhead strategy collapses, so reversible or allosteric backups matter. JAK3's Cys909 is the interesting one, since it can buy isoform selectivity that ATP-site binders struggle with, though acrylamide reactivity across the kinome remains the tox question.

Industry NewsEli LillySTAT News

FDA approves Lilly's Jaypirca for previously untreated CLL and SLL

  • The FDA approved Jaypirca (pirtobrutinib) for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
  • It moves the non-covalent BTK inhibitor from later-line use into the first-line setting.
PointsBased on public reports

First-line is where the BTK market's volume sits, so this is the label that matters commercially. It puts a non-covalent inhibitor directly against the covalent incumbents, where it competes on tolerability and on not depending on the Cys481 bond. Watch how payers and guidelines place it relative to fixed-duration venetoclax regimens.

Industry NewsNovartisSTAT News

Novartis's Remibrutinib Succeeds in Phase III Multiple Sclerosis Trials

  • Novartis reported positive topline Phase III results from the REMODEL-1 and REMODEL-2 trials of remibrutinib in relapsing multiple sclerosis, with the drug outperforming active comparator teriflunomide.
  • Remibrutinib, an oral BTK inhibitor, reduced annualized relapse rate and inflammatory brain lesions versus teriflunomide across both identically designed studies.
  • The trials also showed a positive trend toward slowing disability progression, with a meaningful signal in a preplanned combined analysis.
  • Safety data were reassuring, showing no liver safety signal, consistent with remibrutinib's existing profile in chronic spontaneous urticaria.
  • Novartis plans to present late-breaking data at an upcoming MS conference and pursue global regulatory submissions for this indication.
PointsBased on public reports

Beating teriflunomide isn't the same as beating the field's real benchmark — ocrelizumab, natalizumab, the high-efficacy therapies most MS neurologists already reach for first. Still, the safety data are the real story here. Hepatotoxicity has dogged this drug class, including flags on Sanofi's rival tolebrutinib program, so a clean liver readout is a genuine differentiator, not just noise. If remibrutinib's selectivity truly spares the liver, Novartis gets real separation in the BTK race rather than a me-too label. Add this to the existing CSU approval and Novartis is building an actual platform molecule — one asset, multiple indications, shared manufacturing and commercial muscle. The number to watch next: whether that disability-progression trend holds up, since that's what actually shifts prescribing.